Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells

Cancer Gene Therapy

Volumn 23, Issue 4, 2016, Pages 107-113

  Takasu, A ^a   Masui, A ^a   Hamada, M ^a   Imai, T ^a   Iwai, S ^a   Yura, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1; ONCOLYTIC HERPES VIRUS; PHOSPHATE BUFFERED SALINE; PROPIDIUM IODIDE; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; IMMUNOGENIC CELL DEATH; IMMUNOGENICITY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PYROPTOSIS; SQUAMOUS CELL CARCINOMA CELL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL CULTURE; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANIMALS; CALRETICULIN; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; HMGB1 PROTEIN; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLY(ADP-RIBOSE) POLYMERASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961223683     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.8     Document Type: Article

References (47)

1. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61
3. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079
4. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875
5. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351
6. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21: 39-49
7. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014; 4: 74
8. Rapaport E, Fontaine J. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc Natl Acad Sci USA 1989; 86: 1662-1666
9. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195
10. Müller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004; 255: 332-343
11. Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 2007; 14: 2839-2847
12. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109: 4839-4845
13. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286
14. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100-3104
15. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008; 16: 1637-1642
16. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011; 21: 213-226
17. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080-2089
18. Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S-I, Nakashima T et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006; 126: 1115-1117
19. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771
20. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6: 941-949
21. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-4015
22. First oncolytic viral therapy for melanoma. Cancer Discov 2016; 6: 6. (published online 9 November 2015; doi: 10.1158/2159-8290.CD-NB2015-158v1
23. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670
24. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 810: 6018-6026
25. Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S et al. Virusmediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008; 27: 2375-2381
26. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72: 2609-2621
27. Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 2014; 88: 5263-5276
28. Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L et al. Newcastle disease virotherapy induces long-Term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015; 136: E313-E325
29. Benencia F, Courrèges MC, Conejo-García JR, Mohammed-Hadley A, Coukos G. Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biol Ther 2006; 5: 867-874
30. Borde C, Barnay-Verdier S, Gaillard C, Hocini H, Maréchal V, Gozlan J. Stepwise release of biologically active HMGB1 during HSV-2 infection. PLoS One 2011; 6: e16145
31. Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22: 123-131
32. Meshii N, Takahashi G, Okunaga S, Hamada M, Iwai S, Takasu et al. Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. Cancer Gene Ther 2013; 20: 493-498
33. Takaoka H, Takahashi G, Ogawa F, Imai T, Iwai S, Yura Y. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol J 2011; 8: 294
34. Takahashi G, Meshii N, Hamada M, Iwai S, Yura Y. Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy. J Gen Virol 2013; 94: 726-737
35. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 28: 3723-3728
36. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665-683
37. Chazotte B. Labeling membrane glycoproteins or glycolipids with fluorescent wheat germ agglutinin. Cold Spring Harb Protoc 2011; 2011: pdb.prot5623
38. Vermes I, Haanen C, Steffens-nakken H, Reutelingsperger C. A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51
39. Brumatti G, Sheridan C, Martin SJ. Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells. Methods 2008; 44: 235-240
40. Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci 2004; 19: 124-128
41. Jouan-Lanhouet S, Riquet F, Duprez L, Vanden Berghe T, Takahashi N, Vandenabeele P. Necroptosis, in vivo detection in experimental disease models. Semin Cell Dev Biol 2014; 35: 2-13
42. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-69
43. Colunga AG, Laing JM, Aurelian L. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther 2010; 17: 315-327
44. Peri P, Nuutila K, Vuorinen T, Saukko P, Hukkanen V. Cathepsins are involved in virus-induced cell death in ICP4 and Us3 deletion mutant herpes simplex virus type 1-infected monocytic cells. J Gen Virol 2011; 92: 173-180
45. Croker BA, O'Donnell JA, Gerlic M. Pyroptotic death storms and cytopenia. Curr Opin Immunol 2014; 26: 128-137
46. Chien H, Dix RD. Evidence for multiple cell death pathways during development of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression: apoptosis, necroptosis, and pyroptosis. J Virol 2012; 86: 10961-10978
47. Tan TY, Chu JJ. Dengue virus-infected human monocytes trigger late activation of caspase-1, which mediates pro-inflammatory IL-1β secretion and pyroptosis. J Gen Virol 2013; 94: 2215-2220